IP Library Granted Patent US 9,387,249
Granted Patent B2
US 9,387,249 · App. 12/644,025 · Granted Jul 12, 2016

Methods of treating hypertension with at least one angiotensin II receptor blocker and chlorthalidone

Inventor: Stuart R. Kupfer (Deerfield, IL)
Assignee: Takeda Pharmaceutical Company Limited
A61K45/06A61K31/404A61K31/41A61K31/4184A61K31/4245
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,387,249
App. No.
12/644,025
Granted
Jul 12, 2016
Kind
B2
Abstract

The present invention relates to a method of treating hypertension in a subject or patient needing treatment thereof by administering to said subject or patient at least one angiotensin II receptor blocker in combination with chlorthalidone.

Claims (8)

1. A method of treating hypertension and reducing incidence of hypokalemia in a patient in need of treatment thereof, the method comprising the steps of:

administering to said patient (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 2-ethoxy-1-{[2′-(5-oxo-4,5-dihydro-1,2,4oxadiazol-3-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylate potassium salt in an amount selected from the group consisting of about 40 mg per day and about 80 mg per day, and chlorthalidone in an amount selected from the group consisting of about 12.5 mg per day and 25.0 mg per day, wherein the hypokalemia is greater than the reduction in incidence of hypokalemia is lower than the incidence of hypokalemia provided by 12.5 mg or 25.0 mg per day of chlorthalidone alone.

2. The method of claim 1 , wherein the hypertension is essential hypertension, secondary hypertension, arterial hypertension, pulmonary arterial hypertension or portal vein hypertension.

3. The method of claim 1 , wherein the benzimidazole derivative and chlorthalidone are administered as separate dosage forms.

4. The method of claim 3 , wherein the benzimidazole derivative is administered as a tablet.

5. The method of claim 3 , wherein the chlorthalidone is administered as a tablet.

6. The method of claim 1 , wherein the benzimidazole derivative and chlorthalidone are administered together in a single dosage form.

7. The method of claim 6 , wherein the single dosage form is a tablet.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 26, 2013
From: TAKEDA PHARMACEUTICALS U.S.A., INC.
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 031288/0693 →
CHANGE OF NAME Recorded Apr 2, 2012
From: TAKEDA PHARMACEUTICALS NORTH AMERICA, INC.,
To: TAKEDA PHARMACEUTICALS U.S.A., INC.
Reel/Frame 027971/0541 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 22, 2010
From: KUPFER, STUART R.
To: TAKEDA PHARMACEUTICALS NORTH AMERICA, INC.
Reel/Frame 024273/0386 →
Continuity (2)
Provisional Application 61140281 · Dec 23, 2008
Related Publication 20100204252A1 · Aug 12, 2010